Immunic Inc (IMUX) - Total Assets
Based on the latest financial reports, Immunic Inc (IMUX) holds total assets worth $24.05 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Immunic Inc (IMUX) balance sheet quality index to measure how much of total assets are equity-financed.
Immunic Inc - Total Assets Trend (2011–2025)
This chart illustrates how Immunic Inc's total assets have evolved over time, based on quarterly financial data. Check how tangible is Immunic Inc's equity to evaluate the tangible quality of the company's equity base.
Immunic Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Immunic Inc's total assets of $24.05 Million consist of 95.1% current assets and 4.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 64.4% |
| Accounts Receivable | $4.12 Million | 17.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Immunic Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IMUX stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immunic Inc's current assets represent 95.1% of total assets in 2025, an increase from 44.8% in 2011.
- Cash Position: Cash and equivalents constituted 64.4% of total assets in 2025, up from 40.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 17.1% of total assets.
Immunic Inc Competitors by Total Assets
Key competitors of Immunic Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Immunic Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.75 | 1.77 | 7.35 |
| Quick Ratio | 0.75 | 1.77 | 7.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-7.75 Million | $17.16 Million | $103.92 Million |
Immunic Inc - Advanced Valuation Insights
This section examines the relationship between Immunic Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.72 |
| Latest Market Cap to Assets Ratio | 6.59 |
| Asset Growth Rate (YoY) | -41.1% |
| Total Assets | $24.05 Million |
| Market Capitalization | $158.42 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Immunic Inc's assets at a significant premium (6.59x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Immunic Inc's assets decreased by 41.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Immunic Inc (2011–2025)
The table below shows the annual total assets of Immunic Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $24.05 Million | -41.15% |
| 2024-12-31 | $40.87 Million | -24.74% |
| 2023-12-31 | $54.30 Million | -57.50% |
| 2022-12-31 | $127.75 Million | -8.16% |
| 2021-12-31 | $139.10 Million | -17.13% |
| 2020-12-31 | $167.86 Million | +154.51% |
| 2019-12-31 | $65.95 Million | +340.35% |
| 2018-12-31 | $14.98 Million | -75.20% |
| 2017-12-31 | $60.38 Million | -5.69% |
| 2016-12-31 | $64.03 Million | -28.13% |
| 2015-12-31 | $89.08 Million | -17.58% |
| 2014-12-31 | $108.08 Million | +132.01% |
| 2013-12-31 | $46.59 Million | +129.12% |
| 2012-12-31 | $20.33 Million | +925.32% |
| 2011-12-31 | $1.98 Million | -- |
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative… Read more